<?xml version="1.0" encoding="UTF-8"?>
<rdf:RDF
 xmlns:xsd="http://www.w3.org/2001/XMLSchema#"
 xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#"
 xmlns:owl="http://www.w3.org/2002/07/owl#"
 xmlns:bp="http://www.biopax.org/release/biopax-level3.owl#"
 xml:base="http://www.reactome.org/biopax/91/9818564#">
<owl:Ontology rdf:about="">
 <owl:imports rdf:resource="http://www.biopax.org/release/biopax-level3.owl#" />
</owl:Ontology>

<bp:PathwayStep rdf:ID="PathwayStep40">
 <bp:stepProcess rdf:resource="#BiochemicalReaction38" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep42">
 <bp:stepProcess rdf:resource="#BiochemicalReaction40" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep41">
 <bp:stepProcess rdf:resource="#BiochemicalReaction39" />
</bp:PathwayStep>

<bp:Provenance rdf:ID="Provenance1">
 <bp:name rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Reactome</bp:name>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">http://www.reactome.org</bp:comment>
</bp:Provenance>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction8">
 <bp:evidence rdf:resource="#Evidence11" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">ABL1 phosphorylates PPARG2</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction9">
 <bp:evidence rdf:resource="#Evidence12" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">SCD5 gene expression is stimulated by PPARG2:RXRA:MLL4,(MLL3)-ASCOM complex</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction6">
 <bp:evidence rdf:resource="#Evidence9" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">LPIN1 gene expression is stimulated by PPARG:RXRA:MLL4,(MLL3)-ASCOM complex</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction7">
 <bp:evidence rdf:resource="#Evidence10" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">PLIN4 gene expression is stimulated by PPARG:RXRA:MLL4,(MLL3)-ASCOM complex</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep43">
 <bp:stepProcess rdf:resource="#BiochemicalReaction41" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1">
 <bp:evidence rdf:resource="#Evidence4" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">LIPE gene expression is stimulated by PPARG:RXRA:MLL4,(MLL3)-ASCOM complex</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction4">
 <bp:evidence rdf:resource="#Evidence7" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">SCD gene expression is stimulated by PPARG:RXRA:MLL4,(MLL3)-ASCOM complex</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction5">
 <bp:evidence rdf:resource="#Evidence8" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">DGAT2 gene expression is stimulated by PPARG:RXRA:MLL4,(MLL3)-ASCOM complex</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction2">
 <bp:evidence rdf:resource="#Evidence5" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">PHLDA1 binds PPARG</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction3">
 <bp:evidence rdf:resource="#Evidence6" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">ADIPOQ gene expression is stimulated by PPARG:RXRA:MLL4,(MLL3)-ASCOM complex</bp:displayName>
</bp:BiochemicalReaction>

<bp:BioSource rdf:ID="BioSource1">
 <bp:name rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Homo sapiens</bp:name>
</bp:BioSource>

<bp:PathwayStep rdf:ID="PathwayStep31">
 <bp:stepProcess rdf:resource="#BiochemicalReaction29" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep30">
 <bp:stepProcess rdf:resource="#BiochemicalReaction28" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep37">
 <bp:stepProcess rdf:resource="#BiochemicalReaction35" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep36">
 <bp:stepProcess rdf:resource="#BiochemicalReaction34" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep39">
 <bp:stepProcess rdf:resource="#BiochemicalReaction37" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep38">
 <bp:stepProcess rdf:resource="#BiochemicalReaction36" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep33">
 <bp:stepProcess rdf:resource="#BiochemicalReaction31" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep32">
 <bp:stepProcess rdf:resource="#BiochemicalReaction30" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep35">
 <bp:stepProcess rdf:resource="#BiochemicalReaction33" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep34">
 <bp:stepProcess rdf:resource="#BiochemicalReaction32" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence40">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence41">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence42">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence43">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence44">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep20">
 <bp:stepProcess rdf:resource="#BiochemicalReaction18" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep26">
 <bp:stepProcess rdf:resource="#BiochemicalReaction24" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep25">
 <bp:stepProcess rdf:resource="#BiochemicalReaction23" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep28">
 <bp:stepProcess rdf:resource="#BiochemicalReaction26" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep27">
 <bp:stepProcess rdf:resource="#BiochemicalReaction25" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep22">
 <bp:stepProcess rdf:resource="#BiochemicalReaction20" />
 <bp:stepProcess rdf:resource="#Catalysis2" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep21">
 <bp:stepProcess rdf:resource="#BiochemicalReaction19" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep24">
 <bp:stepProcess rdf:resource="#BiochemicalReaction22" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep23">
 <bp:stepProcess rdf:resource="#BiochemicalReaction21" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence37">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence38">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence39">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep29">
 <bp:stepProcess rdf:resource="#BiochemicalReaction27" />
</bp:PathwayStep>

<bp:Pathway rdf:ID="Pathway2">
 <bp:pathwayOrder rdf:resource="#PathwayStep2" />
 <bp:pathwayComponent rdf:resource="#Pathway3" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence2" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Epigenetic regulation of adipogenesis genes by MLL3 and MLL4 complexes</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">During adipogenesis, the KMT2D (MLL4) complex preferentially localizes to active enhancers, marked by the presence of mono- or dimethylated histone H3 lysine-4 (H3K4me1/2, residue K4 corresponds to residue K5 in nascent histone H3), acetylated H3 lysine-27 (H3K27ac), and the presence of RNA Pol II. KMT2D localizes to these active enhancers together with the adipogenic transcription factors CEBPB, CEBPA, and PPARG, and is especially enriched at high confidence enhancers that are both CEBP and PPARG positive (Lee et al. 2013). Single Kmt2c (Mll3) knockout in mouse brown preadipocytes led to a modest decrease of H3K4me1, while double Kmt2c;Kmt2d (Mll4) knockout led to a global decrease of H3K4me1/2 (Lee et al. 2013). Most MLL4-binding sites are marked by both H3K4me1 and H3K4me2 during adipogenesis (Lee et al. 2013). Double knockout of Kmt2c and Kmt2d in differentiating mouse adipocytes prevented increase in H3K4me1/2, H3K27ac, Mediator complex and RNA Pol II on adipogenic enhancers, specifically on Cebpa and Pparg gene loci (Lee et al. 2013). KMT2D-dependent deposition of H3K4me1/2 marks was also detected on some adipogenic promoters, but was less pronounced than on adipogenic enhancers (Lee et al. 2013). Deletion of Kmt2d significantly decreased expression of genes associated with Kmt2d+ adipogenic enhancers (Lee et al. 2013). The expression of KMT2C, the catalytic subunit of the MLL3 complex, is upregulated during brown adipocyte differentiation (Son et al. 2016).  Transgenic mice that express catalytically inactive form of Kmt2c (Lee, Saha et al. 2008; Lee, Lee et al. 2008) or that have a heterozygous loss of Kmt2d (Kim et al. 2016) are resistant to fatty liver formation induced by high-fat diet. Expression of a large portion of high-fat diet induced genes in mouse liver requires Kmt2d (Kim et al. 2016). Among the defined transcription factors that promote high-fat diet-induced hepatic steatosis (ChREBP, SREBP1c, LXRs, and PPARG), ChREBP and SREBP1c do not interact with KMT2C/D (Kim et al. 2016).  Gomisin N, a lignin isolated from magnolia-vine (Schisandra chinensis) was shown to inhibit, without cytotoxic effects, differentiation of mouse 3T3-L1 preadipocytes by inhibiting mitotic clonal expansion during early adipogenesis (Jang et al. 2017). Gomisin N treatment reduces KMT2D but not KMT2C mRNA levels, and also reduces the mRNA level of adipogenic transcription factors CEBPB, CEBPA, and PPARG, as well as their targets FABP4 (aP2) and FASN (FAS), inhibiting lipid accumulation and formation of lipid droplets, both in 3T3-L1 preadipocytes and in adipose tissue of mice on high fat diet. Gomisin N ameliorates hepatic steatosis in obese mice on high fat diet (Jang et al. 2017).  The epigenomic reader BRD4, essential for both white and brown adipose tissue development but dispensable for adipose tissue maintenance, is enriched on active enhancers during the initial stages of adipogenesis and on promoters that associate with enhancers at terminal stages of adipogenesis (Lee et al. 2017). More than 90% of Brd4 genomic binding sites lose Brd4 in mouse preadipocytes that are double knockout for Kmt2c and Kmt2d (Lee et al. 2017). The majority of Brd4-bound enhancers are co-occupied by Kmt2d, Ep300, Cebpa or Cebpb, and Pparg (Lee et al. 2017). Brd4 knockout does not affect binding of Cebpb and Kmt2d to adipogenesis target genes nor does it affect deposition of activating epigenetic marks, H3K4me1 and H3K27ac, at these genes, but it reduces binding of transcriptional machinery (e.g. Med1, Tbp, RNA Pol II, Cdk9) and mRNA synthesis (Lee et al. 2017). Brd2 and Brd3 may be able to partially compensate for the loss of Brd4 (Lee et al. 2017). Inhibition of Brd proteins by synthetic inhibitor JQ1 inhibits expression of Pparg targets Cepba, Fabp4 and Adipoq induced by rosiglitazone, a synthetic Pparg agonist (Lee et al. 2017). Brd4 was shown to physically associate with Cebpb (Lee et al. 2017). Conditional knockout mice in which Brd4 gene is deleted in progenitor cells of brown adipose tissue and muscle lineages die immediately after birth because of breathing impairment, exhibiting severe reduction in muscle mass and brown adipose tissue (Lee et al. 2017).  Based on mouse studies, at the onset of white and brown adipogenesis the accessory subunit of MLL3 and MLL4 complexes, PAGR1 (also known as PA1) is needed for induction of CEBPB and CEBPD transcription factors (Lee et al. 2020). Based on a study in immortalized mouse brown adipocytes, PAGR1 is recruited to the CEBPB gene promoter by activated CREB1, which is phosphorylated at serine residue S133 (p-S133-CREB1) (Lee et al. 2020). Based on a study in mouse white preadipocyte cell line 3T3-L1, PAGR1 is recruited to CEBPD gene promoter by ligand-activated glucocorticoid receptor (GR) (Lee et al. 2020).  Based on a study conducted using the mouse 3T3-L1 white preadipocyte cell line as a model system, dehydroleucodine, a sesquiterpene lactone isolated from Artemisia douglasiana (California mugwort) halts mitotic clonal expansion at the initiation of white adipogenesis (Abood et al. 2017). Dehydroleucodine decreases the phosphorylation of ERKs and AKT, as well as levels of CCNA, CCND, CDK2, and CDK4, while increasing the level of p27 (CDKN1B), resulting in G0/G1 cell cycle arrest of mouse white preadipocytes (Abood et al. 2017). Dehydroleucodine also downregulates JMJD2B and KMT2D, leading to downregulation of CEBPB and PPARG, respectively (Abood et al. 2017).  Expression of the histone 3 mutant H3.3 K4M in mouse brown preadipocytes impairs adipose tissue development, but when H3.3 K4M is expressed in already differentiated mouse brown adipocytes, the maintenance and thermogenic function of brown adipose tissue are not affected (Jang et al. 2019). </bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway1">
 <bp:pathwayOrder rdf:resource="#PathwayStep1" />
 <bp:pathwayOrder rdf:resource="#PathwayStep43" />
 <bp:pathwayOrder rdf:resource="#PathwayStep42" />
 <bp:pathwayOrder rdf:resource="#PathwayStep41" />
 <bp:pathwayComponent rdf:resource="#Pathway2" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction40" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction41" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction39" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence1" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Epigenetic regulation of gene expression by MLL3 and MLL4 complexes</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">The KMT2C (MLL3) complex, together with the related KMT2D (MLL4) complex, is most similar to Drosophila Trr (Trithorax-related) and mediates hitone H3 lysine-4 (H3K4 - lysine 5 in nascent histone H3) monomethylation, with the establishment of the H3K4me1 epigenetic marks, at transcription enhancers throughout the human genome (For review, please refer to Hu et al. 2013, Piunti and Shilatifard 2016, Klonou et al. 2021).  The MLL3 and MLL4 complexes monomethylate H3K4 at transcription enhancers throughout the human genome, with estimates ranging from approximately 12,000 to over 20,000 sites, depending on the cell type and developmental stage. Full activation of gene expression through MLL3 and MLL4 complex target enhancers appears to require simultaneous monomethylation of H3K4 by MLL3 and/or MLL4 complexes, and acetylation of H3K27 by the histone acetyltransferase p300/CBP, recruited to enhancers through direct interactions with the MLL3 and MLL4 complexes. KDM6A (also known as UTX), a lysine demethylase that acts as an accessory subunit of MLL3 and MLL4 complexes, facilitates H3K27 acetylation by removing inhibitory methyl groups from H3K27, deposited by the Polycomb repressor PRC2 complex (reviewed in Fagan and Dingwall 2019).  KMT2C (also known as MLL3), the catalytic subunit of the MLL3 complex, contains two closely related plant homeodomain (PHD) zinc finger clusters, with 6-7 zinc fingers, in the N-terminal region, and a single PHD zinc finger near the C-terminus, which are involved in protein-protein interactions. The HMG domain in KMT2C enables DNA binding, while the SET domain provides catalytic activity. KMT2C possesses multiple nuclear receptor (NR) interaction motifs (LLXXL or LXXLL), which are important for recruitment of the MLL3 complex to NR-regulated enhancers (reviewed in Fagan and Dingwall 2019).  While H3K4 monomethylation by MLL3 and MLL4 complexes may not be essential for expression of developmental genes, it is likely important for fine tuning of transcription levels and timing, both during normal development and in cancer. Although a broad dispersion of cancer mutations in the coding regions of the KMT2C and KMT2D genes, as well as the presence of many truncating mutations, imply a tumor suppressor role, activating mutations in the SET domains have also been reported, suggesting that a tumor suppressive vs. oncogenic role is context-dependent (reviewed in Fagan and Dingwall 2019).  KMT2C is frequently mutated in cancer. KMT2C may be important for driving hormone-stimulated proliferation of breast cancer cells that are ESR1-positive and ERBB2-negative. In mice, simultaneous overexpression of Pik3ca and inactivation of the Kmt2c blocks differentiation of the mammary gland and leads to increased stem cell self-renewal through HIF pathway activation (reviewed in Fagan and Dingwall 2019).  Non-small cell lung cancer (NSCLC) is characterized by frequent co-occurrence of mutations in KMT2C and KMT2D (also known as MLL4, the catalytic subunit of the MLL4 complex) (reviewed in Fagan and Dingwall 2019).  DNA damage-induced transcription of TP53 target genes requires both KMT2C and KMT2D. KMT2C is also implicated in TP53-dependent DNA double strand break repair in a transcription-independent manner. KTM2C and KMT2D contribute to maintenance of epithelial cell states by negatively regulating the epithelial-to-mesenchymal transition. KMT2C mutations in lung and breast cancer are frequently found in the first PHD that is involved in the interaction with the BAP1 histone deubiquitinating complex, linked to Polycomb repressor complex-dependent gene silencing (reviewed in Fagan and Dingwall 2019).  Heterozygous germline LOF mutations in KTM2C are associated with Kleefstra syndrome-2 and autism spectrum disorder (reviewed in Fagan and Dingwall 2019).  In mouse, Kmt2c and Kmt2d are implicated in enhancer priming and de novo enhancer activation during embryonic development. This function is not essential for the maintenance of cell identity and self-renewal of embryonic stem cells (ESCs) and somatic cells but is necessary for ESC reprogramming during differentiation and for production of induced pluripotent stem cells (iPSCs) (reviewed in Fagan and Dingwall 2019).   Knockout of KMT2D, the catalytic subunit of the MLL4 complex, in human colon carcinoma cell line HCT116, which already harbors inactivating mutations in both alleles of KMT2C (the catalytic subunit of the MLL3 complex), leads to significant global reduction of H3K4 monomethylation (Hu et al. 2013). Knockout studies of KMT2C and KMT2D in HCT116 cells and mouse embryonic fibroblasts (MEFs) implicate at least partially redundant roles of MLL3 and MLL4 complexes in H3K4 monomethylation (Hu et al. 2013). Genome-wide ChIP-seq analysis in both HCT116 cells and MEFs showed that ~80% of the MLL4 peaks are enriched at intergenic and intragenic regions, while only ~20% of the peaks map to transcription start sites (TSS) (Hu et al. 2013). MLL4 binding sites at SAE1 and AP3B1 gene loci in HCT116 cells, and at Nanog and Lefty1 loci in MEFs, are co-occupied by enhancer region markers H3K4me1, EP300, and acetylated H3K27 (Hu et al. 2013). Many of the genes associated with MLL3/MLL4-bound enhancers in HCT116 cells are implicated in intracellular signaling, while genes associated with MLL3/MLL4-independent enhancers tend to be implicated in regulation of gene expression (Hu et al. 2013).  HOXA9, encoded by a target gene of KMT2A (MLL1) and KMT2B (MLL2) complexes, may function as a pioneer factor at de novo enhancers in acute myeloid leukemia (AML) and recruit CEBPA and the MLL3 and MLL4 complexes to enhancers of leukemogenesis-promoting genes (Sun et al. 2018).  KMT2D is frequently mutated in cancer (reviewed in Dhar and Lee 2021) and is one of the most frequently mutated genes in non-Hodgkin lymphoma, such as follicular lymphoma and diffuse large B cell lymphoma, where loss-of-function (LOF) of KMT2D appears to be an early event that cooperates with the over-expression of the BCL2 oncogene. Knockout of Kmt2d in mouse B cell progenitors impairs their differentiation and promotes lymphoma development. KMT2D LOF in lymphoma is associated with reduced H3K4me1 mark at enhancers of multiple tumor suppressor genes (reviewed in Fagan and Dingwall 2019).  KMT2D chromatin enrichment sites significantly overlap with TP53 binding sites. Aberrant transcription associated with TP53 mutations in colon carcinoma is dependent on KMT2D-mediated H3K4 monomethylation. KMT2D can be inactivated through phosphorylation by SGK1, a PI3K effector kinase closely related to AKT1. SGK1 is the estrogen-inducible kinase, whose transcription is collaboratively activated by ESR1 and KMT2D. SGK1-mediated phosphorylation on KMT2D on serine S1331 near the second PHD results in downregulation of H3K4 monomethylation at ESR1-target genes, thus constituting a negative feedback loop (reviewed in Fagan and Dingwall 2019).  Heterozygous germline LOF mutations in KMT2D are associated with Kabuki syndrome-1. Kabuki syndrome patients have a modestly increased predisposition to cancer, in particular lymphoma, Wilms tumor, hepatoblastoma, synovial sarcoma and neuroblastoma. Mice with brain-specific knockout of Kmt2d (Mll4) develop medulloblastoma that shows hyperactivation of Ras and Notch signaling (reviewed in Fagan and Dingwall 2019).  Based on mouse studies, MLL3 and MLL4 complexes play an important role in adipogenesis and myogenesis. Kmt2c KO mice die around birth with no obvious morphological abnormalities in embryonic development, while Kmt2d KO mice show early embryonic lethality around E9.5 (Lee et al. 2013). Pups with Kmt2d KO in precursors of brown preadipocytes and skeletal myocytes are obtained at the expected Mendelian ratio but display marked reduction in back muscles and die immediately after birth due to breathing malfunction, also showing a decrease in brown adipose tissue mass (Lee et al. 2013). In cultured mouse brown preadipocytes, KO of Kmt2d leads to a moderate differentiation defect along with a transient up-regulation of Kmt2c expression, whereas KO of Kmt2c has no effect on adipogenesis, suggesting a more prominent role of KMT2D in development and a partial compensation of KMT2D loss by KMT2C (Lee et al. 2013). KO of Kmt2d 3T3-L1 mouse white preadipocytes inhibits adipogenesis, and Kmt2c and Kmt2d are also required for adipogenesis in mouse embryonic fibroblasts (Lee et al. 2013). By ChIP-seq, the average length of Kmt2d binding regions is between 350 and 400 bp, and the binding regions change dramatically from the preadipocytes stage to the onset of adipogenesis, but are then Kmt2d-binding regions were largely non-overlapping between brown adipocytes and skeletal myocytes (Lee et al. 2013).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway3">
 <bp:pathwayOrder rdf:resource="#PathwayStep3" />
 <bp:pathwayOrder rdf:resource="#PathwayStep4" />
 <bp:pathwayOrder rdf:resource="#PathwayStep7" />
 <bp:pathwayOrder rdf:resource="#PathwayStep8" />
 <bp:pathwayOrder rdf:resource="#PathwayStep5" />
 <bp:pathwayOrder rdf:resource="#PathwayStep6" />
 <bp:pathwayOrder rdf:resource="#PathwayStep40" />
 <bp:pathwayOrder rdf:resource="#PathwayStep9" />
 <bp:pathwayOrder rdf:resource="#PathwayStep20" />
 <bp:pathwayOrder rdf:resource="#PathwayStep26" />
 <bp:pathwayOrder rdf:resource="#PathwayStep25" />
 <bp:pathwayOrder rdf:resource="#PathwayStep28" />
 <bp:pathwayOrder rdf:resource="#PathwayStep27" />
 <bp:pathwayOrder rdf:resource="#PathwayStep22" />
 <bp:pathwayOrder rdf:resource="#PathwayStep21" />
 <bp:pathwayOrder rdf:resource="#PathwayStep24" />
 <bp:pathwayOrder rdf:resource="#PathwayStep23" />
 <bp:pathwayOrder rdf:resource="#PathwayStep29" />
 <bp:pathwayOrder rdf:resource="#PathwayStep31" />
 <bp:pathwayOrder rdf:resource="#PathwayStep30" />
 <bp:pathwayOrder rdf:resource="#PathwayStep15" />
 <bp:pathwayOrder rdf:resource="#PathwayStep37" />
 <bp:pathwayOrder rdf:resource="#PathwayStep14" />
 <bp:pathwayOrder rdf:resource="#PathwayStep36" />
 <bp:pathwayOrder rdf:resource="#PathwayStep17" />
 <bp:pathwayOrder rdf:resource="#PathwayStep39" />
 <bp:pathwayOrder rdf:resource="#PathwayStep16" />
 <bp:pathwayOrder rdf:resource="#PathwayStep38" />
 <bp:pathwayOrder rdf:resource="#PathwayStep11" />
 <bp:pathwayOrder rdf:resource="#PathwayStep33" />
 <bp:pathwayOrder rdf:resource="#PathwayStep10" />
 <bp:pathwayOrder rdf:resource="#PathwayStep32" />
 <bp:pathwayOrder rdf:resource="#PathwayStep13" />
 <bp:pathwayOrder rdf:resource="#PathwayStep35" />
 <bp:pathwayOrder rdf:resource="#PathwayStep12" />
 <bp:pathwayOrder rdf:resource="#PathwayStep34" />
 <bp:pathwayOrder rdf:resource="#PathwayStep19" />
 <bp:pathwayOrder rdf:resource="#PathwayStep18" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction17" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction18" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction19" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction13" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction35" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction14" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction36" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction15" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction37" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction16" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction38" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction8" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction20" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction9" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction21" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction6" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction22" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction7" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction23" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction4" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction5" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction2" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction3" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction28" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction29" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction24" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction25" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction26" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction27" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction31" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction10" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction32" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction11" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction33" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction12" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction34" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction30" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence3" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">MLL4 and MLL3 complexes regulate expression of PPARG target genes in adipogenesis and hepatic steatosis</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">The ligand-activated complex of a master transcription regulator of adipogenesis, nuclear receptor PPARG, and its partner, nuclear receptor RXRA, recruits MLL3 and MLL4 complexes to target gene loci, leading to establishment of activating epigenetic chromatin marks. The existing experimental evidence implies that MLL3-ASCOM and MLL4-ASCOM complexes are recruited to PPARG:RXRA-target loci, as described below.  PPARG isoform PPARG2-positive adipocyte nuclei isolated from visceral adipose tissue show significantly higher expression level of KMT2C, the catalytic subunit of the MLL3 complex, and PAXIP1, a cofactor of MLL3 and KMT2D (MLL4) complexes, than PPARG2-negative nuclei (Yu et al. 2016). Based on mouse studies, PAXIP1 (PTIP), an accessory subunit of MLL3 and MLL4 complexes, is required for adipogenesis in mouse embryonic fibroblasts (MEFs) and primary preadipocytes. PAXIP1-deficient MEFs show significant defects in both PPARG- and CEBPA-stimulated adipogenesis (Cho et al. 2009). Knockout of Paxip1 gene in brown adipose tissue (BAT) leads to significant decrease of BAT in knockout mice, and a significant decrease of expression of markers shared between white adipose tissue and BAT, such as Pparg, Cebpa, and Fabp4, as well as BAT-specific/prevalent markers Prdm16, Cidea, Mpzl2 (Eva1), Ntrk3, Ucp1, Ppargc1a (Pgc1a), Cox5b and Cox8b (Cho et al. 2009). Paxip1 BAT knockout mice are cold intolerant, with impaired cold-mediated induction of genes involved in fatty acid catabolism, such as Cpt1a, Lpl, and Mlycd (Mcd) (Cho et al. 2009).  In prostate cancer, KMT2D and PPARG are overexpressed at the protein level relative to the normal tissue (Zhai et al. 2022). KMT2D knockdown significantly reduces the lipid droplet content in prostate cancer cell lines (Zhai et al. 2022). In prostate cancer tumors, KMT2D mRNA expression significantly correlates with mRNA expression of lipid metabolism genes FASN, ACC, SCD, and ACLY (Zhai et al. 2022). KMT2D knockdown in prostate cancer cell lines leads to significant decrease in the mRNA levels of ACC, ACLY, and FASN (Zhai et al. 2022). Stimulation of PPARG by the synthetic agonist rosiglitazone stimulates lipid synthesis in prostate cancer cell lines, but the effect of rosiglitazone is diminished upon KMT2D knockdown (Zhai et al. 2022).  In addition to regulating genes involved in lipid metabolism, the PPARG:RXRA complex (Nielsen et al. 2008) and MLL3/MLL4 complexes (Jang et al. 2019: supplementary information) may also regulate expression of some of the genes involved in glucose metabolism and the tricarboxylic acid (TCA) cycle.  Hepatic steatosis represents the synthesis and accumulation of triglycerides in hepatocytes which can, if prolonged, lead to the development of non-alcoholic fatty liver disease (NAFLD) that can progress to non-alcoholic steatohepatitis (NASH), ultimately resulting in liver cirrhosis (Hardy et al. 2016). Like Kmt2c (Mll3) delta/delta mice, which express catalytically inactive Kmt2c (Lee, Saha et al. 2008; Lee S., Lee J. et al. 2008), Kmt2d (Mll4)+/- mice, with deletion of one allele of Kmt2d, are resistant to high fat diet-induced hepatic steatosis, with Kmt2d+/- livers accumulating much less fat relative to wild type littermate controls in response to high fat diet feeding (Kim et al. 2016). Bulk transcriptomic analysis of Kmt2d+/- mouse livers shows that the expression of a large portion of high fat diet controlled genes requires Kmt2d (Kim et al. 2016). Among the defined hepatic steatotic transcription factors, which include MLXIPL (ChREBP), SREBF1 (SREBP1) isoform SREBP1c (SREBP 1C), the liver X receptors (LXRs) &#8211; NR1H3 (LXRA) and NR1H2 (LXRB), and PPARG, KMT2D has been reported to associate with LXRs (Lee S., Lee J. et al. 2008) and PPARG (Lee, Saha et al. 2008). No association between mouse orthologs of KMT2D and MLXIPL or SREBP1c could be detected (Kim et al. 2016).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:PathwayStep rdf:ID="PathwayStep15">
 <bp:stepProcess rdf:resource="#BiochemicalReaction13" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep14">
 <bp:stepProcess rdf:resource="#BiochemicalReaction12" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep17">
 <bp:stepProcess rdf:resource="#BiochemicalReaction15" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep16">
 <bp:stepProcess rdf:resource="#BiochemicalReaction14" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep11">
 <bp:stepProcess rdf:resource="#BiochemicalReaction9" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep10">
 <bp:stepProcess rdf:resource="#BiochemicalReaction8" />
 <bp:stepProcess rdf:resource="#Catalysis1" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep13">
 <bp:stepProcess rdf:resource="#BiochemicalReaction11" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep12">
 <bp:stepProcess rdf:resource="#BiochemicalReaction10" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep19">
 <bp:stepProcess rdf:resource="#BiochemicalReaction17" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep18">
 <bp:stepProcess rdf:resource="#BiochemicalReaction16" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence20">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence21">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence22">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence23">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence24">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence25">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction39">
 <bp:evidence rdf:resource="#Evidence42" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">PAXIP1:PAGR1 complex, NCOA6 and KDM6A bind MLL4 complex</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction35">
 <bp:evidence rdf:resource="#Evidence38" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">PPARG2 transcription is stimulated by PPARG2:RXRA:MLL4,(MLL3)-ASCOM complex</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction36">
 <bp:evidence rdf:resource="#Evidence39" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Corepressors are released from liganded PPARG:RXRA heterodimer</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction37">
 <bp:evidence rdf:resource="#Evidence40" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Unliganded PPARG:RXRA heterodimer recruits corepressors to target gene loci</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction38">
 <bp:evidence rdf:resource="#Evidence41" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">PPARG binds RXRA</bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence9">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence8">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence7">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence6">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence5">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction40">
 <bp:evidence rdf:resource="#Evidence43" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">PAXIP1 binds PAGR1</bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence4">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction41">
 <bp:evidence rdf:resource="#Evidence44" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">PAXIP1:PAGR1 complex, NCOA6 and KDM6A bind MLL3 complex</bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence3">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence15">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence2">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence16">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence17">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence18">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence19">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence30">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence31">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence32">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence33">
</bp:Evidence>

<bp:Catalysis rdf:ID="Catalysis2">
 <bp:controlled rdf:resource="#BiochemicalReaction20" />
</bp:Catalysis>

<bp:Evidence rdf:ID="Evidence34">
</bp:Evidence>

<bp:Catalysis rdf:ID="Catalysis1">
 <bp:controlled rdf:resource="#BiochemicalReaction8" />
</bp:Catalysis>

<bp:Evidence rdf:ID="Evidence35">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence36">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction28">
 <bp:evidence rdf:resource="#Evidence31" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">PEX11A gene expression is stimulated by PPARG:RXRA:MLL4,(MLL3)-ASCOM complex</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction29">
 <bp:evidence rdf:resource="#Evidence32" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">CEBPA gene expression is stimulated by PPARG:RXRA:MLL4,(MLL3)-ASCOM complex</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction24">
 <bp:evidence rdf:resource="#Evidence27" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">PLIN1 gene expression is stimulated by PPARG:RXRA:MLL4,(MLL3)-ASCOM complex</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction25">
 <bp:evidence rdf:resource="#Evidence28" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">FABP4 gene expression is stimulated by PPARG:RXRA:MLL4,(MLL3)-ASCOM complex</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction26">
 <bp:evidence rdf:resource="#Evidence29" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">PLIN2 gene expression is stimulated by PPARG:RXRA:MLL4,(MLL3)-ASCOM complex</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction27">
 <bp:evidence rdf:resource="#Evidence30" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">GPAM gene expression is stimulated by PPARG2:RXRA:MLL4,(MLL3)-ASCOM complex</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction31">
 <bp:evidence rdf:resource="#Evidence34" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">LPL gene expression is stimulated by PPARG:RXRA:MLL4,(MLL3)-ASCOM complex</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction32">
 <bp:evidence rdf:resource="#Evidence35" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">MLL4-ASCOM,(MLL3-ASCOM) complex is recruited to ligand- and coactivator-bound PPARG:RXRA heterodimer</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction33">
 <bp:evidence rdf:resource="#Evidence36" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">PDK4 gene expression is stimulated by PPARG:RXRA:MLL4,(MLL3)-ASCOM complex</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction34">
 <bp:evidence rdf:resource="#Evidence37" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">ABL1 binds PPARG2</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction30">
 <bp:evidence rdf:resource="#Evidence33" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">RXRA binds ligands</bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence26">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence27">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence28">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence29">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep3">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep4">
 <bp:stepProcess rdf:resource="#BiochemicalReaction2" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1">
 <bp:stepProcess rdf:resource="#Pathway2" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2">
 <bp:stepProcess rdf:resource="#Pathway3" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep7">
 <bp:stepProcess rdf:resource="#BiochemicalReaction5" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep8">
 <bp:stepProcess rdf:resource="#BiochemicalReaction6" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep5">
 <bp:stepProcess rdf:resource="#BiochemicalReaction3" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep6">
 <bp:stepProcess rdf:resource="#BiochemicalReaction4" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction17">
 <bp:evidence rdf:resource="#Evidence20" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">THRSP gene expression is stimulated by PPARG2:RXRA:MLL4,(MLL3)-ASCOM complex</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction18">
 <bp:evidence rdf:resource="#Evidence21" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Coactivators are recruited to liganded PPARG:RXRA heterodimer</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep9">
 <bp:stepProcess rdf:resource="#BiochemicalReaction7" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction19">
 <bp:evidence rdf:resource="#Evidence22" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">ACSS3 gene expression is stimulated by PPARG2:RXRA:MLL4(MLL3)-ASCOM complex</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction13">
 <bp:evidence rdf:resource="#Evidence16" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">PNPLA2 gene expression is stimulated by PPARG:RXRA:MLL4,(MLL3)-ASCOM complex</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction14">
 <bp:evidence rdf:resource="#Evidence17" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">MGLL gene expression is stimulated by PPARG:RXRA:MLL4,(MLL3)-ASCOM complex</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction15">
 <bp:evidence rdf:resource="#Evidence18" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">ACSL1 gene expression is stimulated by PPARG:RXRA:MLL4,(MLL3)-ASCOM complex</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction16">
 <bp:evidence rdf:resource="#Evidence19" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">PPARG:RXRA heterodimer binds target gene loci</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction20">
 <bp:evidence rdf:resource="#Evidence23" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">KMT2D,(KMT2C) complex monomethylates nucleosomes at PPARG:RXRA-bound enhancers</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction21">
 <bp:evidence rdf:resource="#Evidence24" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">ANGPTL4 gene expression is stimulated by PPARG:RXRA:MLL4,(MLL3)-ASCOM complex</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction22">
 <bp:evidence rdf:resource="#Evidence25" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">ELOVL5 gene expression is stimulated by PPARG2:RXRA:MLL4(MLL3)-ASCOM complex</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction23">
 <bp:evidence rdf:resource="#Evidence26" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">PPARG binds ligands</bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence10">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence11">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence12">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence13">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence14">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction10">
 <bp:evidence rdf:resource="#Evidence13" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">CIDEC gene expression is stimulated by PPARG:RXRA:MLL4,(MLL3)-ASCOM complex</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction11">
 <bp:evidence rdf:resource="#Evidence14" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">AGPAT2 gene expression is stimulated by PPARG:RXRA:MLL4,(MLL3)-ASCOM complex</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction12">
 <bp:evidence rdf:resource="#Evidence15" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">CD36 gene expression is stimulated by PPARG:RXRA:MLL4,(MLL3)-ASCOM complex</bp:displayName>
</bp:BiochemicalReaction>
</rdf:RDF>